Patents by Inventor Kazuaki Takami

Kazuaki Takami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970483
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Sasaki, Yasutomi Asano, Kazuaki Takami, Masaki Seto, Haruhi Ando
  • Publication number: 20230357220
    Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6?-(phenyl)-2H-(1,2?-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).
    Type: Application
    Filed: May 20, 2021
    Publication date: November 9, 2023
    Inventors: Tomoaki HASUI, Satoshi MIKAMI, JR., Toru YAMASHITA, Shinji NAKAMURA, Shinji MORIMOTO, Toshihiro IMAEDA, Kazuaki TAKAMI, Masaki DAINI, Hiroyuki KAKEI, Minoru NAKAMURA, Fumie YAMAGUCHI, Chunxiang WANG, Sachie TAKASHIMA, Makoto KAMATA, Yuya OGURO, Shuhei IKEDA
  • Publication number: 20230348435
    Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).
    Type: Application
    Filed: May 20, 2021
    Publication date: November 2, 2023
    Inventors: Tomoaki HASUI, Satoshi MIKAMI, Toru YAMASHITA, Shinji NAKAMURA, Shinji MORIMOTO, Toshihiro IMAEDA, Kazuaki TAKAMI, Masaki DAINI, Hiroyuki KAKEI, Minoru NAKAMURA, Fumie YAMAGUCHI, Chunxiang WANG, Sachie TAKASHIMA, Shogo HASHIZUME
  • Publication number: 20230303541
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: December 14, 2022
    Publication date: September 28, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu SASAKI, Masaki SETO, Kazuaki TAKAMI, Haruhi ANDO
  • Patent number: 11702419
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: July 18, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
  • Patent number: 11560372
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: January 24, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Sasaki, Masaki Seto, Kazuaki Takami, Haruhi Ando
  • Patent number: 11459325
    Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
  • Publication number: 20220289679
    Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Yuta TANAKA, Keiko KAKEGAWA, Takahito KASAHARA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Tomohiro OHASHI, Zenichi IKEDA, Florian PUENNER, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
  • Publication number: 20220274982
    Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 1, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
  • Patent number: 11407748
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Tomoaki Hasui, Tohru Yamashita, Shinji Morimoto, Hidekazu Tokuhara, Norio Oyabu, Masami Yamada, Atsuko Ochida, Kazuaki Takami, Xin Liu
  • Publication number: 20220041581
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: February 10, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu SASAKI, Yasutomi ASANO, Hironobu MAEZAKI, Ayumu SATO, Kazuaki TAKAMI, Masaki SETO, Haruhi ANDO, Shuji KITAMURA, Steve L. SWANN
  • Patent number: 11236099
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • Publication number: 20220017530
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • Publication number: 20210380565
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu SASAKI, Yasutomi ASANO, Kazuaki TAKAMI, Masaki SETO, Haruhi ANDO
  • Patent number: 11186565
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 30, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
  • Publication number: 20210340114
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Application
    Filed: April 9, 2021
    Publication date: November 4, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
  • Publication number: 20210332053
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: March 15, 2021
    Publication date: October 28, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
  • Publication number: 20210292308
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: September 23, 2021
    Inventors: Shinobu SASAKI, Masaki SETO, Kazuaki TAKAMI, Haruhi ANDO
  • Publication number: 20210139491
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: June 19, 2018
    Publication date: May 13, 2021
    Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
  • Patent number: 10975043
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: April 13, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki